Skip to main content
S 3565 115th Congress Senate Health

Opioid Advocacy Transparency Act of 2018

Introduced: October 10, 2018 See on congress.gov
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Oct 10, 2018
Read twice and referred to the Committee on Finance.
Oct 10, 2018
Introduced in Senate
 Plain-English summary Congressional Research Service

Opioid Advocacy Transparency Act of 2018

This bill expands reporting requirements related to the ownership and investment interests of certain patient-advocacy organizations.

Under current law, a manufacturer of drugs, devices, or medical supplies that are covered under Medicaid or Medicare must regularly report on any payment or transfer of value by the manufacturer to a "covered recipient," defined as either a physician who is not an employee of the manufacturer or a teaching hospital. The bill expands the definition of "covered recipient," for purposes of this requirement, to also include patient-advocacy organizations that advocate on issues related to opioids. Furthermore, with respect to transfers of value to such organizations, the bill subjects not only manufacturers but also pharmaceutical trade associations to the reporting requirement.

What's happening now October 10, 2018

Read twice and referred to the Committee on Finance.

 Committees of jurisdiction 1